| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 379K | 2.32M | 6.79M | 9.33M | 9.22M | 9.56M | 10.9M |
| Revenue Growth % | - | 5.12% | 1.93% | 0.37% | -0.01% | 0.04% | 0.14% |
| Cost of Goods Sold | 8.44M | 0 | 37.6M | 101.18M | 1.39M | 2.1M | 0 |
| COGS % of Revenue | 22.26% | - | 5.54% | 10.85% | 0.15% | 0.22% | - |
| Gross Profit | -8.06M | 2.32M | -30.82M | -91.86M | 7.84M | 7.46M | 10.9M |
| Gross Margin % | -21.26% | 1% | -4.54% | -9.85% | 0.85% | 0.78% | 1% |
| Gross Profit Growth % | - | 1.29% | -14.29% | -1.98% | 1.09% | -0.05% | 0.46% |
| Operating Expenses | 10.88M | 19.65M | 13.46M | 26.2M | 186.75M | 243.06M | 389.83M |
| OpEx % of Revenue | 28.7% | 8.47% | 1.98% | 2.81% | 20.25% | 25.42% | 35.77% |
| Selling, General & Admin | 2.44M | 5.11M | 13.46M | 26.2M | 37.73M | 54.19M | 86.24M |
| SG&A % of Revenue | 6.44% | 2.2% | 1.98% | 2.81% | 4.09% | 5.67% | 7.91% |
| Research & Development | 8.44M | 14.54M | 37.6M | 101.18M | 150.4M | 190.97M | 303.59M |
| R&D % of Revenue | 22.26% | 6.27% | 5.54% | 10.85% | 16.31% | 19.98% | 27.86% |
| Other Operating Expenses | 0 | 0 | -37.6M | -101.18M | -1.39M | -2.1M | 0 |
| Operating Income | -10.5M | -17.33M | -44.28M | -118.05M | -178.91M | -235.6M | -378.94M |
| Operating Margin % | -27.7% | -7.47% | -6.52% | -12.66% | -19.4% | -24.64% | -34.77% |
| Operating Income Growth % | - | -0.65% | -1.55% | -1.67% | -0.52% | -0.32% | -0.61% |
| EBITDA | -10.12M | -16.98M | -43.9M | -117.41M | -177.53M | -233.5M | -376.16M |
| EBITDA Margin % | -26.69% | -7.32% | -6.47% | -12.59% | -19.25% | -24.42% | -34.52% |
| EBITDA Growth % | - | -0.68% | -1.59% | -1.67% | -0.51% | -0.32% | -0.61% |
| D&A (Non-Cash Add-back) | 383K | 348K | 373K | 639K | 1.39M | 2.1M | 2.78M |
| EBIT | -10.5M | -17.35M | -44.15M | -118.05M | -178.91M | -235.6M | -378.94M |
| Net Interest Income | -718K | -7.39M | -3K | 104K | 4.97M | 23.97M | 56.88M |
| Interest Income | 0 | 0 | 206K | 104K | 4.97M | 23.97M | 56.88M |
| Interest Expense | 718K | 7.39M | 209K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -718K | -7.4M | -78K | 42K | 4.92M | 23.38M | 56.63M |
| Pretax Income | -11.22M | -24.73M | -44.35M | -118.01M | -174M | -212.22M | -322.3M |
| Pretax Margin % | -29.59% | -10.67% | -6.54% | -12.65% | -18.86% | -22.2% | -29.58% |
| Income Tax | 718K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1.06% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -11.93M | -24.73M | -44.35M | -118.01M | -174M | -212.22M | -322.3M |
| Net Margin % | -31.49% | -10.67% | -6.54% | -12.65% | -18.86% | -22.2% | -29.58% |
| Net Income Growth % | - | -1.07% | -0.79% | -1.66% | -0.47% | -0.22% | -0.52% |
| Net Income (Continuing) | -11.22M | -24.73M | -44.35M | -118.01M | -174M | -212.22M | -322.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.58 | -0.86 | -2.05 | -2.85 | -3.34 | -2.91 | -2.89 |
| EPS Growth % | - | -0.48% | -1.38% | -0.39% | -0.17% | 0.13% | 0.01% |
| EPS (Basic) | -0.58 | -0.86 | -2.05 | -2.85 | -3.34 | -2.91 | -2.89 |
| Diluted Shares Outstanding | 20.68M | 37.51M | 21.66M | 41.43M | 52.16M | 73.01M | 111.58M |
| Basic Shares Outstanding | 20.68M | 37.51M | 21.66M | 41.43M | 52.16M | 73.01M | 111.58M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.24M | 95.68M | 331.68M | 411.14M | 622.94M | 611.31M | 1.54B |
| Cash & Short-Term Investments | 3.09M | 94.58M | 328.14M | 405.54M | 610.73M | 595.35M | 1.5B |
| Cash Only | 3.09M | 94.58M | 321.46M | 320.45M | 340.4M | 185.08M | 219.87M |
| Short-Term Investments | 0 | 0 | 6.68M | 85.09M | 270.33M | 410.27M | 1.28B |
| Accounts Receivable | 0 | 0 | 1.2M | 900K | 3.88M | 8.62M | 28.22M |
| Days Sales Outstanding | - | - | 64.54 | 35.22 | 153.34 | 329.23 | 945.31 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 152K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 740K | 1.23M | 2.22M | 16.44M | 15.86M | 17.25M | 21.61M |
| Property, Plant & Equipment | 702K | 631K | 1.92M | 15.59M | 15.01M | 16.65M | 18.29M |
| Fixed Asset Turnover | 0.54x | 3.68x | 3.53x | 0.60x | 0.61x | 0.57x | 0.60x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 38K | 600K | 298K | 850K | 849K | 596K | 3.32M |
| Total Assets | 3.98M | 96.91M | 333.9M | 427.58M | 638.8M | 628.55M | 1.56B |
| Asset Turnover | 0.10x | 0.02x | 0.02x | 0.02x | 0.01x | 0.02x | 0.01x |
| Asset Growth % | - | 23.34% | 2.45% | 0.28% | 0.49% | -0.02% | 1.49% |
| Total Current Liabilities | 4.62M | 10.24M | 14.59M | 29.66M | 51.91M | 80.68M | 98.02M |
| Accounts Payable | 1.56M | 2.31M | 7.75M | 2.81M | 4.64M | 8.81M | 8.46M |
| Days Payables Outstanding | 67.71 | - | 75.18 | 10.12 | 1.22K | 1.53K | - |
| Short-Term Debt | 2.75M | 2.77M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1000K | 0 | 0 | 1000K | 1000K | 1000K |
| Other Current Liabilities | 305K | 0 | 3.69M | 4.86M | 11.19M | 14.34M | 3.66M |
| Current Ratio | 0.70x | 9.35x | 22.74x | 13.86x | 12.00x | 7.58x | 15.73x |
| Quick Ratio | 0.70x | 9.35x | 22.74x | 13.86x | 12.00x | 7.58x | 15.73x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 40.49M | 152.03M | 13.09M | 16.49M | 8.82M | 47.11M | 40.92M |
| Long-Term Debt | 7.58M | 1.77M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 393K | 938K | 9.96M | 7.58M | 6.21M | 2.96M |
| Deferred Tax Liabilities | 0 | 134.72M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 32.92M | 45K | 12.15M | 6.53M | 0 | 0 | 0 |
| Total Liabilities | 45.11M | 162.26M | 27.68M | 46.15M | 60.73M | 127.79M | 138.94M |
| Total Debt | 10.32M | 4.94M | 938K | 11.73M | 10.69M | 9.85M | 6.8M |
| Net Debt | 7.23M | -89.64M | -320.52M | -308.72M | -329.71M | -175.23M | -213.07M |
| Debt / Equity | - | - | 0.00x | 0.03x | 0.02x | 0.02x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -14.62x | -2.35x | -211.85x | - | - | - | - |
| Total Equity | -41.13M | -65.36M | 306.22M | 381.43M | 578.08M | 500.76M | 1.42B |
| Equity Growth % | - | -0.59% | 5.69% | 0.25% | 0.52% | -0.13% | 1.85% |
| Book Value per Share | -1.99 | -1.74 | 14.14 | 9.21 | 11.08 | 6.86 | 12.77 |
| Total Shareholders' Equity | -41.13M | -65.36M | 306.22M | 381.43M | 578.08M | 500.76M | 1.42B |
| Common Stock | 426K | 1K | 4K | 5K | 7K | 8K | 12K |
| Retained Earnings | -41.55M | -22.18M | -66.54M | -184.55M | -358.54M | -570.76M | -893.07M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -33.12M | -134.72M | -5K | -187K | -2.7M | 125K | 2.9M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.65M | 2.49M | -37.12M | -94.81M | -136.27M | -119.06M | -300.87M |
| Operating CF Margin % | -25.47% | 1.07% | -5.47% | -10.17% | -14.77% | -12.45% | -27.61% |
| Operating CF Growth % | - | 1.26% | -15.91% | -1.55% | -0.44% | 0.13% | -1.53% |
| Net Income | -11.22M | -24.73M | -44.35M | -118.01M | -174M | -212.22M | -322.3M |
| Depreciation & Amortization | 383K | 348K | 373K | 639K | 1.39M | 2.1M | 2.78M |
| Stock-Based Compensation | 60K | 406K | 4.31M | 17.06M | 27.14M | 38.22M | 51.36M |
| Deferred Taxes | 0 | 0 | 84K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 447K | 7.11M | 139K | 163K | -615K | -8.3M | -18.15M |
| Working Capital Changes | 671K | 19.36M | 2.33M | 5.34M | 9.82M | 61.13M | -14.56M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 780K | 436K | 5.75M | 6.04M | 18.32M | 1.77M | 35.18M |
| Cash from Investing | -49K | -235K | -7.79M | -82.52M | -189.96M | -130.07M | -854.2M |
| Capital Expenditures | -49K | -235K | -1.09M | -3.74M | -2.82M | -4.23M | -7.07M |
| CapEx % of Revenue | 0.13% | 0.1% | 0.16% | 0.4% | 0.31% | 0.44% | 0.65% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -82.52M | -187.13M | 0 | 0 |
| Cash from Financing | 5.14M | 89.23M | 272.04M | 176.32M | 346.17M | 93.86M | 1.19B |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | -106K | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 162K | 65K | 466K | 1.64M | 1.39M | 2.13M | 191.81M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -9.7M | 2.25M | -38.21M | -98.55M | -139.09M | -123.29M | -307.94M |
| FCF Margin % | -25.6% | 0.97% | -5.63% | -10.57% | -15.08% | -12.9% | -28.26% |
| FCF Growth % | - | 1.23% | -17.94% | -1.58% | -0.41% | 0.11% | -1.5% |
| FCF per Share | -0.47 | 0.06 | -1.76 | -2.38 | -2.67 | -1.69 | -2.76 |
| FCF Conversion (FCF/Net Income) | 0.81x | -0.10x | 0.84x | 0.80x | 0.78x | 0.56x | 0.93x |
| Interest Paid | 0 | 322K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -36.83% | -34.32% | -36.27% | -39.34% | -33.47% |
| Return on Invested Capital (ROIC) | - | - | - | -303.16% | -83.58% | -61.58% | -36.97% |
| Gross Margin | -2125.86% | 100% | -454.03% | -984.95% | 84.96% | 78.02% | 100% |
| Net Margin | -3148.81% | -1066.58% | -653.53% | -1265.38% | -1886.33% | -2219.87% | -2957.71% |
| Debt / Equity | - | - | 0.00x | 0.03x | 0.02x | 0.02x | 0.00x |
| Interest Coverage | -14.62x | -2.35x | -211.85x | - | - | - | - |
| FCF Conversion | 0.81x | -0.10x | 0.84x | 0.80x | 0.78x | 0.56x | 0.93x |
| Revenue Growth | - | 511.87% | 192.67% | 37.41% | -1.09% | 3.64% | 13.99% |
| 2024 | |
|---|---|
| Reportable | 10.9M |
| Reportable Growth | - |
Avidity Biosciences, Inc. (RNA) reported $20.9M in revenue for fiscal year 2024. This represents a 5406% increase from $0.4M in 2018.
Avidity Biosciences, Inc. (RNA) grew revenue by 14.0% over the past year. This is steady growth.
Avidity Biosciences, Inc. (RNA) reported a net loss of $549.8M for fiscal year 2024.
Avidity Biosciences, Inc. (RNA) has a return on equity (ROE) of -33.5%. Negative ROE indicates the company is unprofitable.
Avidity Biosciences, Inc. (RNA) had negative free cash flow of $595.4M in fiscal year 2024, likely due to heavy capital investments.